Involvement of the estrogen receptor β in genistein-induced expression of p21waf1/cip1 in PC-3 prostate cancer cells

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 709-714

  Matsumura, Kentaro ^a   Tanaka, Tomoaki ^a   Kawashima, Hidenori ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Estrogen receptor ; Genistein; p21; Prostate cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTROGEN RECEPTOR BETA; GENISTEIN; LUCIFERASE; PROTEIN P27; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER PATIENT; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESTROGEN RECEPTOR BETA; GENE EXPRESSION; GENISTEIN; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 42549087663     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Zaridze DG, Boyle P and Smans M: International trends in prostatic cancer. Int J Cancer 33: 223-230, 1984.
2. Donn AS and Muir CS: Prostatic cancer: some epidemiological features. Bull Cancer 72: 381-390, 1985.
3. Messina MJ, Persky V, Setchell KD and Barnes S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21: 113-131, 1994.
4. Messina MJ: Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 70: 439S-450S, 1999.
5. Messina M and Barnes S: The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83: 541-546, 1991.
6. Barnes S: Effect of genistein on in vitro and in vivo models of cancer. J Nutr 125: 777S-783S, 1995.
7. Barnes S, Peterson TG and Coward L: Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem Suppl 22: 181-187, 1995.
8. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595, 1987.
9. Raschke M, Rowland IR, Magee PJ and Pool-Zobel BL: Genistein protects prostate cells against hydrogen peroxide-induced DNA damage and induces expression of genes involved in the defence against oxidative stress. Carcinogenesis 27: 2322-2330, 2006.
10. Murata M, Midorikawa K, Koh M, Umezawa K and Kawanishi S: Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. Biochemistry 43: 2569-2577, 2004.
11. Kyle E, Neckers L, Takimoto C, Curt G and Bergan R: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 51: 193-200, 1997.
12. Miekus K and Madeja Z: Genistein inhibits the contact-stimulated migration of prostate cancer cells. Cell Mol Biol Lett 12: 348-361, 2007.
13. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB and Larsen AK: Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49: 5111-5117, 1989.
14. Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y and Uemura H: Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 12: 73-80, 2005.
15. Jagadeesh S, Kyo S and Banerjee PP: Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res 66: 2107-2115, 2006.
16. Kobayashi T, Nakata T and Kuzumaki T: Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 176: 17-23, 2002.
17. Choi YH, Lee WH, Park KY and Zhang L: p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91: 164-173, 2000.
18. WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32: 123-131, 1998.
19. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S and Hursting SD: Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 29: 92-102, 2000.
20. Imamov O, Lopatkin NA and Gustafsson JA: Estrogen receptor beta in prostate cancer. N Engl J Med 351: 2773-2774, 2004.
21. Ho SM, Leung YK and Chung I: Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann NY Acad Sci 1089: 177-193, 2006.
22. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL and Corey E: Metastases of prostate cancer express estrogen receptor-beta. Urology 64: 814-820, 2004.
23. Fixemer T, Remberger K and Bonkhoff H: Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54: 79-87, 2003.
24. Cheng J, Lee EJ, Madison LD and Lazennec G: Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 566: 169-172, 2004.
25. Pravettoni A, Mornati O, Martini PG, Marino M, Colciago A, Celotti F, Motta M and Negri-Cesi P: Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol 263: 46-54, 2007.
26. Mak P, Leung YK, Tang WY, Harwood C and Ho SM: Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 8: 896-904, 2006.
27. Zhang Z, Li M, Wang H, Agrawal S and Zhang R: Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100: 11636-11641, 2003.
28. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg and Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263, 1998.
29. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N and Leitman DC: Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276: 17808-17814, 2001.
30. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS: Differential ligand activation of estrogen receptors ERalpha and ERbeta at API sites. Science 277: 1508-1510, 1997.
31. Zou A, Marschke KB, Arnold KE, Berger EM, Fitzgerald P, Mais DE and Allegretto EA: Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol Endocrinol 13: 418-430, 1999.
32. Schultz JR, Petz LN and Nardulli AM: Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem 280: 347-354, 2005.
33. Cerillo G, Rees A, Manchanda N, Reilly C, Brogan I, White A and Needham M: The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner. J Steroid Biochem Mol Biol 67: 79-88, 1998.
34. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE and Ho SM: Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164: 2003-2012, 2004.